A case of allergic bronchopulmonary aspergillosis successfully treated with mepolizumab

• Published in: BMC pulmonary medicine Vol. 18; no. 1; pp. 53 - 5
• Main Authors: Terashima, Takeshi, Shinozaki, Taro, Iwami, Eri, Nakajima, Takahiro, Matsuzaki, Tatsu
• Format: Journal Article
• Language: English
• Published: England BioMed Central 27.03.2018; BMC
• Subjects: Adrenal Cortex Hormones - therapeutic use; Adrenergic beta-Agonists - therapeutic use; Allergic bronchopulmonary aspergillosis; Anti-Asthmatic Agents - therapeutic use; Antibodies, Monoclonal, Humanized - therapeutic use; Antifungal Agents - therapeutic use; Aspergillosis, Allergic Bronchopulmonary - complications; Aspergillosis, Allergic Bronchopulmonary - drug therapy; Aspergillosis, Allergic Bronchopulmonary - physiopathology; Asthma - complications; Asthma - drug therapy; Asthma - physiopathology; Bronchial asthma; Case Report; Disease Progression; Eosinophilia; Female; Forced Expiratory Volume; Humans; Itraconazole - therapeutic use; Leukotriene Antagonists - therapeutic use; Mepolizumab; Middle Aged; Muscarinic Antagonists - therapeutic use; Theophylline - therapeutic use; Bronchial asthma; Allergic bronchopulmonary aspergillosis; Eosinophilia; Mepolizumab

Allergic bronchopulmonary aspergillosis (ABPA) is an allergic pulmonary disease comprising a complex hypersensitivity reaction to Aspergillus fumigatus. Clinical features of ABPA are wheezing, mucoid impaction, and pulmonary infiltrates. Oral corticosteroids and anti-fungal agents are standard thera...